Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMBENYL vs NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AMBENYL is a combination product containing codeine (opioid agonist) and bromodiphenhydramine (antihistamine). Codeine binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception; bromodiphenhydramine antagonizes histamine H1 receptors, producing antitussive and sedative effects.
Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.
Cough suppression,Symptomatic relief of cough associated with colds or allergies
Moderate to severe pain relief; combinations are used to reduce abuse potential.
Each 5 m L contains codeine phosphate 10 mg and diphenhydramine hydrochloride 12.5 mg. Adults: 10 m L (2 teaspoonfuls) orally every 4-6 hours as needed; maximum 40 m L per day.
Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.
Codeine: 2.5-3.5 h (terminal) with CYP2D6 poor metabolizers up to 6 h. Guaifenesin: 1-2 h.
Pentazocine has an elimination half-life of 2-3 hours in healthy adults, which may be prolonged in patients with hepatic impairment. Naloxone has a terminal half-life of 0.5-1.5 hours in adults, with a rapid decline in plasma levels; the short half-life limits its duration of opioid antagonism.
Codeine is metabolized via CYP2D6 to morphine (active), CYP3A4 to norcodeine, and to a lesser extent via glucuronidation; bromodiphenhydramine is metabolized via CYP450 enzymes, primarily CYP2D6.
Pentazocine is metabolized primarily by hepatic conjugation (glucuronidation) and oxidation via CYP2C19 and CYP2D6; naloxone is extensively metabolized by the liver, primarily via glucuronidation (UGT2B7).
Renal: 60% unchanged codeine, 20% codeine-6-glucuronide; biliary/fecal: 20% as metabolites. Guaifenesin: renal 95% as unchanged drug and metabolites.
Pentazocine is primarily metabolized in the liver and excreted in urine as conjugates of glucuronide and sulfate, with about 60% of a dose excreted renally within 24 hours as metabolites and unchanged drug (less than 5% unchanged). Naloxone undergoes extensive hepatic metabolism to naloxone-3-glucuronide, which is excreted renally; approximately 50% of a dose is excreted as conjugates in urine within 6 hours.
Codeine: 7-25% (albumin). Guaifenesin: negligible.
Pentazocine: Approximately 35-65% bound to plasma proteins (mainly albumin). Naloxone: Approximately 32-45% bound to plasma proteins (mainly albumin).
Codeine: 3-6 L/kg (extensive tissue distribution). Guaifenesin: 1-2 L/kg.
Pentazocine: Vd ~2-3 L/kg, indicating extensive tissue distribution. Naloxone: Vd ~2-3 L/kg, also indicating wide distribution.
Codeine: oral 90% (first-pass metabolism). Guaifenesin: oral 100% (well absorbed).
Oral pentazocine: 20-30% due to first-pass metabolism. Intramuscular pentazocine: 100%. Subcutaneous pentazocine: 100%. Oral naloxone: <2% due to extensive first-pass metabolism. Intramuscular and subcutaneous naloxone: 100%. Intravenous: 100% for both.
GFR 30-50 m L/min: use with caution, reduce dose by 25-50% and monitor for CNS depression. GFR <30 m L/min: avoid use or use with extreme caution; codeine accumulation risk.
GFR 30-50 m L/min: Administer every 6 hours; GFR 10-29 m L/min: Administer every 8-12 hours; GFR <10 m L/min: Administer every 12 hours or consider alternative.
Child-Pugh A: no adjustment needed. Child-Pugh B: use with caution, consider 50% dose reduction. Child-Pugh C: avoid use.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% or extend interval; Child-Pugh Class C: Avoid use.
Not recommended for children under 6 years. Children 6-12 years: 5 m L (1 teaspoonful) orally every 4-6 hours; maximum 20 m L per day. Children >12 years: adult dosing.
Not recommended for children under 12 years. For older children (≥12 years): Pentazocine 50 mg (with naloxone 0.5 mg) orally every 3-4 hours as needed; maximum 6 tablets daily.
Initiate at 5 m L every 6 hours due to increased sensitivity to anticholinergic and CNS depressant effects; monitor for confusion, sedation, and urinary retention.
Initiate with half the usual adult dose (one-half tablet) and titrate carefully due to increased sensitivity and risk of respiratory depression.
Risk of respiratory depression, especially in children; risk of opioid addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; CYP2D6 ultra-rapid metabolizers may convert codeine to morphine at higher rates, leading to fatal respiratory depression.
Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of life-threatening respiratory depression when used with benzodiazepines or other CNS depressants.
Respiratory depression; use in children <12 years contraindicated; risk of opioid-induced hyperalgesia; central nervous system depression; sedation; constipation; urinary retention; hypotension; anticholinergic effects; potential for misuse, abuse, and addiction; serotonin syndrome if used with other serotonergic drugs; adrenal insufficiency; risk of severe hypotension in volume-depleted patients; interactions with CNS depressants.
Respiratory depression; hypotension; increased intracranial pressure; seizure risk (pentazocine); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; interaction with MAOIs; risk of dependence and withdrawal; gastrointestinal obstruction; impaired renal or hepatic function; head injury.
Children <12 years; post-operative management in children <18 years after tonsillectomy/adenoidectomy; respiratory depression; acute or severe bronchial asthma; known hypersensitivity to codeine, bromodiphenhydramine, or any component; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days; gastrointestinal obstruction; paralytic ileus.
Hypersensitivity to pentazocine or naloxone; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; patients receiving MAOIs or within 14 days.
Zolpidem absorption is delayed and reduced when taken with food, especially high-fat meals. To achieve rapid onset of sleep, take on an empty stomach. Avoid grapefruit juice as it may increase zolpidem levels.
No specific food interactions are reported for this combination. However, grapefruit juice may theoretically affect metabolism via CYP3A4 (pentazocine is metabolized by CYP3A4), but clinical significance is unknown. Advise patients to maintain a consistent diet.
FDA Pregnancy Category C. First trimester: Limited data; potential for fetal malformations (cleft palate, cardiac defects) based on animal studies with high-dose antihistamines. Second and third trimesters: Risk of neonatal respiratory depression, irritability, and withdrawal if used near term. Avoid in third trimester due to risk of premature closure of ductus arteriosus (codeine component).
Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Third trimester: Chronic use may cause fetal dependence; neonatal withdrawal syndrome reported. High doses near term may cause neonatal respiratory depression.
Codeine is excreted in breast milk (M/P ratio ~2.5); risk of neonatal opioid toxicity (CNS depression). Diphenhydramine may inhibit lactation and cause drowsiness in infant. Contraindicated during breastfeeding due to possible severe adverse reactions in neonates.
Pentazocine is excreted in breast milk in small amounts (estimated relative infant dose <3%). Naloxone is poorly bioavailable orally. Generally considered compatible with breastfeeding; monitor infant for sedation or poor feeding. M/P ratio for pentazocine is approximately 1.0.
No established safe dose during pregnancy; avoid use. If unavoidable, use lowest effective dose for shortest duration. Pharmacokinetic changes (increased clearance, volume of distribution) may require dose adjustment, but due to risks, alternative therapy is recommended.
No established dose adjustments for pregnancy; however, pharmacokinetic changes (increased volume of distribution, enhanced clearance) may require higher or more frequent doses of pentazocine for adequate analgesia. Use lowest effective dose and shortest duration.
Ambien (zolpidem) is a non-benzodiazepine sedative-hypnotic used primarily for short-term insomnia. Avoid co-administration with alcohol or other CNS depressants. Use the lowest effective dose, especially in elderly patients, due to increased risk of falls and cognitive impairment. Monitor for complex sleep behaviors (e.g., sleep-driving). Tablet should be taken immediately before bedtime, not with or after a meal to avoid delayed onset.
Naloxone in this fixed-dose combination is included to deter opioid abuse by reversing euphoria. The pentazocine component is a mixed agonist-antagonist opioid; naloxone has poor oral bioavailability but becomes active parenterally, precipitating withdrawal in opioid-dependent individuals. Use with caution in patients with impaired renal or hepatic function. Monitor for respiratory depression, especially in opioid-naive patients, as pentazocine alone can cause respiratory depression.
Take zolpidem exactly as prescribed, only when you have at least 7-8 hours to devote to sleep.,Do not take zolpidem with alcohol or other sedatives as this can cause severe drowsiness and dangerous side effects.,Avoid driving or operating machinery the morning after taking zolpidem, as it may cause drowsiness, dizziness, or impaired coordination.,Report any unusual behaviors during sleep, such as walking, eating, or driving, to your doctor immediately.,Do not crush, chew, or split the extended-release tablets; swallow them whole.
Take exactly as prescribed; do not crush or inject tablets, as injected naloxone can cause severe withdrawal in opioid-dependent individuals.,This medication contains naloxone to discourage misuse; injection will cause withdrawal symptoms.,Report any signs of withdrawal (e.g., nausea, vomiting, sweating, agitation) or breathing difficulty.,Avoid alcohol and other central nervous system depressants as they increase risk of respiratory depression.,Do not use with other opioids unless directed, as effects are unpredictable.,Keep out of reach of children; accidental ingestion may cause severe respiratory depression.
No interactions on record
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMBENYL vs NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, answered by our medical review team.
AMBENYL is a Antitussive/Antihistamine Combination that works by AMBENYL is a combination product containing codeine (opioid agonist) and bromodiphenhydramine (antihistamine). Codeine binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception; bromodiphenhydramine antagonizes histamine H1 receptors, producing antitussive and sedative effects.. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMBENYL and NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMBENYL is: Each 5 m L contains codeine phosphate 10 mg and diphenhydramine hydrochloride 12.5 mg. Adults: 10 m L (2 teaspoonfuls) orally every 4-6 hours as needed; maximum 40 m L per day.. The standard adult dose of NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is: Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMBENYL and NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMBENYL is classified as Category C. FDA Pregnancy Category C. First trimester: Limited data; potential for fetal malformations (cleft palate, cardiac defects) based on animal studies with high-dose antihistamines. Se. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.